Oragenics, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: OGEN · Form: 8-K · Filed: Mar 1, 2024 · CIK: 1174940
Sentiment: neutral
Topics: material-agreement, equity-sale, disclosure
TL;DR
Oragenics filed an 8-K detailing a new material agreement and equity sales.
AI Summary
On February 27, 2024, Oragenics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and provided a Regulation FD disclosure. Additional details regarding other events and financial statements/exhibits are included in the filing.
Why It Matters
This 8-K filing indicates significant corporate activity for Oragenics, Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- February 27, 2024 (date) — Date of earliest event reported
- 1990 Main Street Suite 750 Sarasota, FL 34236 (address) — Principal executive offices
- 813 - 286-7900 (phone_number) — Registrant's telephone number
FAQ
What type of material definitive agreement did Oragenics, Inc. enter into?
The filing states that Oragenics, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the summary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 27, 2024.
What is Oragenics, Inc.'s principal executive office address?
Oragenics, Inc.'s principal executive office is located at 1990 Main Street Suite 750 Sarasota, FL 34236.
What is the registrant's telephone number?
The registrant's telephone number is 813 - 286-7900.
What are the main items reported in this 8-K filing?
The main items reported are entry into a material definitive agreement, unregistered sales of equity securities, Regulation FD disclosure, other events, and financial statements and exhibits.
Filing Stats: 1,326 words · 5 min read · ~4 pages · Grade level 12 · Accepted 2024-03-01 16:05:20
Key Financial Figures
- $1.50 — ommon stock at a price to the public of $1.50 per share (the "Underwritten Shares").
- $1.395 — n Shares from the Company at a price of $1.395 per share. The Company also granted the
- $1.875 — in the Offering at an exercise price of $1.875 per share. The Offering closed on March
- $2.1 million — e gross proceeds from the Offering were $2.1 million before deducting underwriting discounts
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex1-1.htm (EX-1.1) — 534KB
- ex4-1.htm (EX-4.1) — 117KB
- ex4-2.htm (EX-4.2) — 74KB
- ex5-1.htm (EX-5.1) — 15KB
- ex99-1.htm (EX-99.1) — 10KB
- ex5-1_001.jpg (GRAPHIC) — 21KB
- 0001493152-24-008489.txt ( ) — 1165KB
- ogen-20240227.xsd (EX-101.SCH) — 3KB
- ogen-20240227_lab.xml (EX-101.LAB) — 33KB
- ogen-20240227_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 OTHER EVENTS
ITEM 8.01 OTHER EVENTS. Updated Description of Registrant's Securities. The Company is providing an updated Description of Securities, effective as of the Closing, which is attached hereto as Exhibit 4.2. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement dated February 27, 2024 between Oragenics, Inc. and ThinkEquity LLC. 4.1 Form of Representative's Warrants. 4.2 Description of Securities. 5.1 Opinion of Shumaker, Loop & Kendrick, LLP. 99.1 Closing Press Release Dated March 1, 2024. 104 Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 1 st day of March, 2024. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Financial Officer